Calyxt, Inc. CLXT
6.30 0.00 (+0.00%)
At closeMay 31, 2023, 4:00 PM EDT
6.01 Day range 7.77
52-week range unavailable
- Market cap
- 31.33M
- Revenue (ttm)
- 167.00K
- Shares out
- 4.97M
- Forward P/E
- -2.33
- Volume
- 254.09K
- Open
- 6.16
- Previous close
- 6.30
- Day's range
- 6.01 – 7.77
- Beta
- 2.04
- Analysts
- Hold
- Price target
- 7.25 (+15.1%)
- Earnings date
- May 1, 2023
No chart data for this range yet.
Key statistics
- Enterprise value
- 39.50M
- PEG ratio
- 0.00
- Price / sales
- 187.63
- Price / book
- 11.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 31.20%
- Free cash flow
- -13.29M
- Total cash
- 2.05M
- Total debt
- 14.74M
- Return on equity
- -189.52%
- Short % of float
- 4.71%
- 50-day average
- 19.15
- 200-day average
- 13.77
Analyst view
Consensus: hold
Hold
Price target (mean) 7.25 +15.1% upside
Now 6.30
- Target (low)
- 4.50
- Target (mean)
- 7.25
- Target (high)
- 10.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
May 1, 2023
Expected May 1, 2023. Consensus EPS estimate -0.60.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 1, 2023 | Mar 1, 2023 | -0.60 | — | — | — |
| Mar 2, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | -1.50 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -1.50 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -1.80 | — | — | — |
| Mar 3, 2022 | Dec 1, 2021 | -2.30 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 4, 2022 | Canaccord Genuity | main | — | Buy |
| Nov 2, 2021 | Roth Capital | init | — | Buy |
| Dec 15, 2020 | Berenberg | init | — | Buy |
| Dec 10, 2020 | HC Wainwright & Co. | init | — | Buy |
| Jul 28, 2020 | Canaccord Genuity | init | — | Buy |
About Calyxt, Inc.
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company to enhance the quality of alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- calyxt.com
News
Stocks That Hit 52-Week Lows On Wednesday 
Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
CALYXT INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Calyxt, Inc. – CLXT 
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
What Penny Stocks Trends Can Help You Profit in 2023? 
5 Penny Stocks To Watch After Big News This Week 
Why Is Calyxt (CLXT) Stock Up 140% Today? 
Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company 
Calyxt, Inc. (CLXT) Q3 2022 Earnings Call Transcript
Your note
Sign in to keep a note on CLXT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARR MICHAEL A | Chief Executive Officer | Stock Award(Grant) | Feb 28, 2023 | 918,297 |
| DUMONT PHILIPPE | Director | Stock Award(Grant) | May 26, 2021 | 27,614 |
| FREY TRAVIS | Chief Technology Officer | Stock Award(Grant) | Feb 28, 2023 | 692,537 |
| FRIMERMAN DEBRA H. | General Counsel | Stock Award(Grant) | Feb 28, 2023 | 688,457 |
| KOSCHAK WILLIAM | Chief Financial Officer | Stock Award(Grant) | Feb 28, 2023 | 696,007 |
| KOZICZ-STANKIEWICZ ANNA EWA | Director | Stock Award(Grant) | May 26, 2021 | 24,089 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 1.09% | 54,036 | 340.43K | Mar 30, 2023 |
| California, University of-Regents | 1.01% | 50,180 | 316.13K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 0.39% | 19,227 | 121.13K | Mar 30, 2023 |
| Millennium Management Llc | 0.35% | 17,377 | 109.47K | Mar 30, 2023 |
| Blackrock Inc. | 0.30% | 14,677 | 92.47K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.30% | 14,886 | 93.78K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.04% | 19,227 | 121.13K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.02% | 7,975 | 50.24K | Feb 27, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.01% | 6,265 | 39.47K | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 3,797 | 23.92K | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.00% | 1,478 | 9.31K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.00% | 1,420 | 8.95K | Feb 27, 2023 |